Audentes Therapeutics (NASDAQ:BOLD) was downgraded by equities researchers at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating in a research note issued to investors on Tuesday, The Fly reports.
A number of other research firms have also weighed in on BOLD. William Blair reaffirmed a “hold” rating on shares of Audentes Therapeutics in a research report on Wednesday, August 7th. Robert W. Baird upgraded Audentes Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Tuesday. Guggenheim downgraded Audentes Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday. BidaskClub cut Audentes Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, November 8th. Finally, Zacks Investment Research downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $42.00.
Shares of BOLD opened at $28.61 on Tuesday. Audentes Therapeutics has a fifty-two week low of $17.95 and a fifty-two week high of $41.65. The firm’s 50-day simple moving average is $27.71 and its two-hundred day simple moving average is $33.11. The stock has a market cap of $1.33 billion, a PE ratio of -8.41 and a beta of 1.77.
Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.07) by $0.07. During the same quarter in the previous year, the business earned ($0.97) EPS. On average, sell-side analysts forecast that Audentes Therapeutics will post -4.13 EPS for the current fiscal year.
In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 14,426 shares of Audentes Therapeutics stock in a transaction on Friday, November 8th. The stock was sold at an average price of $30.00, for a total value of $432,780.00. Following the completion of the sale, the chief executive officer now owns 127,820 shares of the company’s stock, valued at approximately $3,834,600. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Louis G. Lange sold 10,000 shares of the business’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $32.16, for a total value of $321,600.00. Following the completion of the transaction, the director now owns 276,044 shares of the company’s stock, valued at approximately $8,877,575.04. The disclosure for this sale can be found here. Corporate insiders own 5.30% of the company’s stock.
Large investors have recently made changes to their positions in the company. Meeder Asset Management Inc. increased its holdings in Audentes Therapeutics by 578.5% in the 2nd quarter. Meeder Asset Management Inc. now owns 726 shares of the biotechnology company’s stock worth $27,000 after buying an additional 619 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Audentes Therapeutics by 50.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,990 shares of the biotechnology company’s stock worth $113,000 after buying an additional 1,005 shares during the last quarter. Rhumbline Advisers raised its position in Audentes Therapeutics by 1.8% in the 3rd quarter. Rhumbline Advisers now owns 61,051 shares of the biotechnology company’s stock worth $1,715,000 after buying an additional 1,070 shares during the last quarter. Aperio Group LLC purchased a new position in Audentes Therapeutics in the 2nd quarter worth about $46,000. Finally, Swiss National Bank lifted its stake in Audentes Therapeutics by 2.1% during the 2nd quarter. Swiss National Bank now owns 67,500 shares of the biotechnology company’s stock valued at $2,556,000 after acquiring an additional 1,400 shares during the period. 98.08% of the stock is currently owned by hedge funds and other institutional investors.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Further Reading: What are different types of coverage ratios?
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.